Eagle Pharmaceuticals (EGRX) Q2 results: Revenues: $56.7M (-4.4%); Product sales: $29.4M (+27.8%); Royalty revenue: $27.3M (-24.8%).
BELRAPZO sales were $15.4M, +90.1% Y/Y
RYANODEX sales were $2.9M, down 59.7% Y/Y.
Net Income: $6.7M (+148.1%); EPS: $0.48 (+182.4%); Non-GAAP Net Income: $11.8M (-19.7%); Non-GAAP EPS: $0.84 (-11.6%); CF Ops: $48.6M.
Previously: Eagle Pharmaceuticals EPS beats by $0.01, beats on revenue(Aug. 8)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.